The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression
Open accessAbstract
Previously we reported that proteasome inhibitors were able to overcome Bcl-2-mediated protection from apoptosis. Here we show that inhibition of the proteasome activity in Bcl-2-overexpressing cells accumulates the proapoptotic Bax protein to mitochondria/cytoplasm, where it interacts to Bcl-2 protein. This event was followed by release of mitochondrial cytochrome c into the cytosol and activation of caspase-mediated apoptosis. In contrast, proteasome inhibition did not induce any apparent changes in Bcl-2 protein levels. In addition, treatment with a proteasome inhibitor increased levels of ubiquitinated forms of Bax protein, without any effects on Bax mRNA expression. We also established a cell-free Bax degradation assay in which an in vitro -translated, 35 S-labeled Bax protein can be degraded by a tumor cell protein extract, inhibitable by addition of a proteasome inhibitor or depletion of the proteasome or ATP. The Bax degradation activity can be reconstituted in the proteasome-depleted supernatant by addition of a purified 20S proteasome or proteasome-enriched fraction. Finally, by using tissue samples of human prostate adenocarcinoma, we demonstrated that increased levels of Bax degradation correlated well with decreased levels of Bax protein and increased Gleason scores of prostate cancer. Our studies strongly suggest that ubiquitin/proteasome-mediated Bax degradation is a novel survival mechanism in human cancer cells and that selective targeting of this pathway should provide a unique approach for treatment of human cancers, especially those overexpressing Bcl-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., & Earnshaw, W. C. (1994) · Nature · doi:10.1038/371346a0 · Cited by 2,562
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Mechanisms and Genes of Cellular Suicide
Steller, H. (1995) · Science · doi:10.1126/science.7878463 · Cited by 2,479
Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583
Protease activation during apoptosis: Death by a thousand cuts?
Martin, S. J., & Green, D. R. (1995) · Cell · doi:10.1016/0092-8674(95)90422-0 · Cited by 1,309
Bossy‐Wetzel, E., Newmeyer, D. D., & Green, D. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.1.37 · Cited by 1,225
Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentinc, M., Draetta, G. F., Jessup, J. M., & Pagano, M. (1997) · Nature Medicine · doi:10.1038/nm0297-231 · Cited by 1,031
Cited by
Proteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington, W. J., Lee, K. P., & Boise, L. H. (2006) · Blood · doi:10.1182/blood-2005-08-3531 · Cited by 1,143
Molecular biology of human papillomavirus infection and cervical cancer
Doorbar, J. (2006) · Clinical Science · doi:10.1042/cs20050369 · Cited by 1,072
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Self-citationDoorbar, J. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.12.006 · Cited by 856
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & P. Dou, Q. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519752 · Cited by 795
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Chen, D., Cui, Q. C., Yang, H., & Dou, Q. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2126 · Cited by 674
Self-citationYang, H., Chen, D., Cui, Q. C., Yuan, X., & Dou, Q. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4529 · Cited by 586
Self-citationThe proteasome: a novel target for cancer chemotherapy
Almond, J., & Cohen, G. (2002) · Leukemia · doi:10.1038/sj.leu.2402417 · Cited by 538
Ester Bond-containing Tea Polyphenols Potently Inhibit Proteasome Activity in Vitro and in Vivo
Nam, S., Smith, D. M., & Dou, Q. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004209200 · Cited by 504
Self-citationThe BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Jana, N. R. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1049 · Cited by 452
Heat Shock Protein 70 (Hsp70) as an Emerging Drug Target
Evans, C. G., Chang, L., & Gestwicki, J. E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100054f · Cited by 436
O-GlcNAc Modification Is an Endogenous Inhibitor of the Proteasome
Zhang, F., Su, K., Yang, X., Bowe, D. B., Paterson, A. J., & Kudlow, J. E. (2003) · Cell · doi:10.1016/s0092-8674(03)00974-7 · Cited by 433
Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition
Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2258 · Cited by 410
Storr, S. J., Carragher, N. O., Frame, M. C., Parr, T., & Martin, S. G. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3050 · Cited by 400
Jung, T., Catalgol, B., & Grune, T. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.04.001 · Cited by 389
Deadly encounter: ubiquitin meets apoptosis
Jesenberger, V., & Jentsch, S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm731 · Cited by 355
Oxidative Modification and Inactivation of the Proteasome during Coronary Occlusion/Reperfusion
Bulteau, A.-L., Lundberg, K. C., Humphries, K. M., Sadek, H. A., Szweda, P. A., Friguet, B., & Szweda, L. I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100142200 · Cited by 355
Bistability in Apoptosis: Roles of Bax, Bcl-2, and Mitochondrial Permeability Transition Pores
Bagci, E. Z., Vodovotz, Y., Billiar, T. R., Ermentrout, G. B., & Bahar, I. (2006) · Biophysical Journal · doi:10.1529/biophysj.105.068122 · Cited by 345
Deubiquitinase-targeting chimeras for targeted protein stabilization
Henning, N. J., Boike, L., Spradlin, J. N., Ward, C. C., Liu, G., Zhang, E., Belcher, B. P., Brittain, S. M., Hesse, M. J., Dovala, D., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00971-2 · Cited by 344
Gao, G., & Dou, Q. P. (2001) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20010101)80:1<53::aid-jcb60>3.0.co;2-e · Cited by 310
Self-citationDietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells
Chen, D., Daniel, K. G., Chen, M. S., Kuhn, D. J., Landis-Piwowar, K. R., & Dou, Q. P. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.02.022 · Cited by 306
Self-citationDou, Q., & Zonder, J. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140804154511 · Cited by 275
Self-citationProtein damage, repair and proteolysis
Chondrogianni, N., Petropoulos, I., Grimm, S., Georgila, K., Catalgol, B., Friguet, B., Grune, T., & Gonos, E. S. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.09.001 · Cited by 256
Li, D., Ueta, E., Kimura, T., Yamamoto, T., & Osaki, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03323.x · Cited by 255
THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY
Voorhees, P. M., & Orlowski, R. Z. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141300 · Cited by 247
Bonora, M., & Pinton, P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00302 · Cited by 208
Cancer cell signaling pathways targeted by spice-derived nutraceuticals
Sung, B., Prasad, S., Yadav, V. R., & Aggarwal, B. B. (2012) · Nutrition and Cancer · doi:10.1080/01635581.2012.630551 · Cited by 204
DRAM1 regulates apoptosis through increasing protein levels and lysosomal localization of BAX
Guan, J.-J., Zhang, X.-D., Sun, W., Qi, L., Wu, J.-C., & Qin, Z.-H. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.546 · Cited by 105
Clinical development of novel proteasome inhibitors for cancer treatment
Yang, H., Zonder, J. A., & Dou, Q. P. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903002074 · Cited by 85
Self-citationOh, J.-M., Kim, S.-H., Cho, E.-A., Song, Y.-S., Kim, W.-H., & Juhnn, Y.-S. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp318 · Cited by 80
The unfolded protein response and cancer: A brighter future unfolding?
Scriven, P., Brown, N. J., Pockley, A. G., & Wyld, L. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0150-5 · Cited by 67
Metadata
- Authors
- Li, B., & Dou, Q. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-03-21
- Volume
- 97
- Issue
- 8
- Pages
- 3850-3855
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2024846074
- Cited by
- 446
- References
- 30
- FWCI
- 9.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.